The most immediate threat to AstraZeneca's margin structure is the Inflation Reduction Act's Medicare price negotiation program, which selected Farxiga for the first round of negotiations in 2022 with Maximum Fair Prices taking effect in 2026, and Croquence for the second round with prices effective in 2027. Farxiga, which generated $7.7 billion in 2024 and is the company's largest single product, faces a double hit in 2026: the IRA-mandated price reduction coincides with the loss of market exclusivity that will also trigger generic competition, compressing revenue from what is currently AstraZeneca's most important revenue driver. While management has described the impact as manageable due to the drug's continued growth in non-Medicare segments and international markets, the confluence of government price controls and generic entry on the same product in the same year represents a structural challenge without precedent in the company's modern history. Analysts estimate that U.S. Farxiga revenue could decline by 30% to 40% in the first year of generic competition, creating a $2 billion to $3 billion revenue gap that must be filled by accelerating growth in oncology, rare disease, and the emerging weight management pipeline. The company must also navigate the complex transition of Farxiga patients to generic alternatives while maintaining physician relationships and formulary positioning for its remaining SGLT2 indications. Beyond the IRA, AstraZeneca faces intensifying competitive pressure in oncology, its largest and most profitable segment. Tagrisso, which dominates the EGFR-mutated non-small cell lung cancer market with $6.8 billion in annual sales, now faces competition from next-generation EGFR inhibitors in development at competitors including Johnson & Johnson and Pfizer. The MARIPOSA trial for Johnson & Johnson's lazertinib and amivantamab combination has shown competitive data in first-line EGFR-mutated lung cancer, threatening Tagrisso's 70% market share. Lynparza, the PARP inhibitor that generated approximately $2.8 billion in 2024, lost exclusivity in 2024 and has already experienced significant value erosion with the launch of more than 16 generic brands in major markets, a headwind that will accelerate through 2025 and 2026. The generic erosion of Lynparza is particularly damaging because the drug had been a growth driver in prostate, pancreatic, and ovarian cancer, and its loss removes a diversified revenue stream across multiple tumor types. In the rare disease segment, Soliris, the predecessor to Ultomiris, faces patent expiration in 2025, and while AstraZeneca has successfully converted the majority of patients to the longer-acting Ultomiris, the transition is not complete and biosimilar threats to the complement inhibitor class remain a long-term risk. The company's operations in China, which represented a substantial portion of Emerging Markets revenue, are under severe regulatory and legal pressure following the October 2024 detention of AstraZeneca China president Leon Wang by Chinese authorities amid allegations that former employees falsified genetic tests to secure reimbursement for Tagrisso and illegally imported cancer drugs including Enhertu, Imfinzi, and Imjudo from Hong Kong. This investigation, part of a broader national anti-corruption campaign targeting healthcare, has forced AstraZeneca to reorganize its China leadership and creates uncertainty in a market where the company had planned to invest $15 billion through 2030. The China risk is compounded by the potential for reimbursement restrictions on Tagrisso if the genetic test falsification allegations are proven, which could limit access to the drug for patients who genuinely need it. Additionally, the company's $50 billion U.S. manufacturing investment commitment, announced in July 2025, carries execution risk amid volatile capital markets, construction cost inflation, and the potential for changes in U.S. trade policy including Section 232 tariffs on pharmaceutical imports, against which AstraZeneca negotiated a three-year delay in October 2025. The company must also manage the scientific and commercial risks of its ambitious pipeline, which includes more than 100 Phase III studies and novel modalities such as cell therapy, gene therapy, and oral GLP-1 weight management candidates, any one of which could fail in late-stage trials and destroy billions in expected future revenue. The AZD5004 oral GLP-1 program, while promising, faces a crowded market dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which together generated more than $30 billion in 2024. The competitive environment in respiratory and immunology is also intensifying, with Regeneron and Sanofi's Dupixent dominating the severe asthma and chronic rhinosinusitis with nasal polyps markets at $13.9 billion in 2024 sales, while Tezspire, though growing at 86%, remains a distant challenger. Finally, AstraZeneca faces ongoing geopolitical risks related to its China operations, where the anti-corruption investigation could expand, and its U.S. operations, where tariff policy and pharmaceutical pricing reform remain unpredictable. The company's reliance on alliance partnerships, particularly with Daiichi Sankyo for Enhertu and Amgen for Tezspire, creates dependency risks if these partners change strategic priorities or demand renegotiation of profit-sharing terms.